FDA to Review Restrictions on Compounding Peptides Following Push from HHS Secretary

The U.S. Food and Drug Administration (FDA) is taking the first steps toward potentially easing restrictions on several peptide injections. In a federal notice released Wednesday, April 15, 2026, the agency announced it will convene a meeting of an outside pharmacy advisory panel in July to determine if compounding pharmacies should be allowed to manufacture seven specific peptides.

This move comes amid significant pressure from Health and Human Services Secretary Robert F. Kennedy Jr., who has pledged to “complete the war at FDA” and reduce regulatory red tape regarding peptides and other supplements.

What Are Peptides and Why Are They Controversial?

Peptides are short chains of amino acids that the human body produces naturally. Even as some peptides are well-studied and FDA-approved as commercial drugs—such as insulin and GLP-1s (glucagon-like peptide-1)—many synthetic versions have gained popularity through wellness influencers and celebrities associated with the Make America Healthy Again (MAHA) movement.

These synthetic peptides are often marketed for a variety of unproven uses, including:

• Anti-aging and muscle building
• Quick recovery from injuries
• Treatment for obesity, wound healing, and ulcerative colitis

Secretary Kennedy has described himself as a “big fan” of these products, stating in February that he has used them personally to treat injuries.

The Conflict: Safety Concerns vs. Regulatory Access

The tension surrounding these substances stems from a 2023 FDA decision to place several popular peptides into a restricted category. The agency barred these substances from compounding due to potential significant safety risks, including liver, kidney, and heart problems, as well as cancer.

The Case of BPC-157

One prominent example is BPC-157. According to FDA documentation, compounded drugs containing BPC-157 may pose risks for immunogenicity depending on the route of administration. The agency also cited complexities regarding active pharmaceutical ingredient (API) characterization and peptide-related impurities, noting a lack of sufficient safety information to determine if the drug causes harm in humans.

The HHS Perspective

Secretary Kennedy disputes these safety claims, arguing that the agency lacks proof of such concerns. He has asserted that the previous administration “illegally moved” these drugs onto the restricted list, which he claims created a “gray market” where consumers order peptides from overseas suppliers via the internet.

What Happens Next?

The FDA will now rely on its outside advisory panel during the July meeting to review the seven peptides in question. The panel’s review will determine whether the current restrictions are justified or if compounding pharmacies should be granted permission to produce these substances for clinical use.

Frequently Asked Questions

Why were these peptides restricted in 2023?

The FDA identified potential safety risks, including heart, kidney, liver, and cancer concerns, and noted that for some substances, there was insufficient information to ensure human safety.

What is the difference between a commercial peptide drug and a compounded one?

Commercial peptide drugs, like insulin, undergo rigorous FDA approval processes. Compounded peptides are created by pharmacies, and the FDA has expressed concern over the characterization and purity of these synthetic versions.

Will these peptides be available immediately?

No. The FDA is currently in the “first step” of the process. A decision will likely follow the advisory panel’s meeting in July.